




**Supplemental Figure 1. Tregs so not require activation by their cognate peptide:DC combination to suppress.** A, Tconv ( $2.5 \times 10^4$ ) were incubated with DCs ( $6.25 \times 10^3$ ) and Tregs ( $1.25 \times 10^4$ ) in the presence of peptide (Ova<sub>326-339</sub> and PCC<sub>88-104</sub>;  $0.3 \mu\text{M}$ ) for 68 h, pulsed with [<sup>3</sup>H]thymidine for the last 8 h of culture and Tconv proliferation measured. A representative from 3 experiments is shown. B, Tconv ( $2.5 \times 10^4$ ) were incubated with DCs ( $6.25 \times 10^3$ ) and Tregs of varying concentrations in the presence of peptide (Ova<sub>326-339</sub> or PCC<sub>88-104</sub>;  $0.3 \mu\text{M}$ ) for 68 h, pulsed with [<sup>3</sup>H]thymidine for the last 8 h of culture and Tconv proliferation measured. A representative from 2-5 experiments is shown. \*\*,  $p < 0.005$ , \*,  $p < 0.05$ .




**Supplementary Figure 2.** Treg development in *Rag1*<sup>-/-</sup> AND and OTII TCR transgenic mice. **A.** Spleens and lymph nodes from indicated mice were processed, stained with antibodies against CD4 and Fxp3 and analyzed by flow cytometry. Fxp3 unstained control is shown. **B.** Thymi from AND.*Rag1*<sup>+/-</sup>.*Foxp3*<sup>gfp</sup>, AND.*Rag1*<sup>-/-</sup>.*Foxp3*<sup>gfp</sup> AND.*Rag1*<sup>-/-</sup> mice were processed, stained with anti-CD4 antibody and analyzed by flow cytometry.



**Supplementary Figure 3.** Foxp3<sup>+</sup> Tregs from AND transgenic mice on a *Rag1*<sup>-/-</sup> background only express the clonotypic, AND-specific TCR-Vβ3. Lymph nodes from *AND.Rag1*<sup>+/-</sup>.*Foxp3*<sup>gfp</sup> (control) and *AND.Rag1*<sup>-/-</sup>.*Foxp3*<sup>gfp</sup> mice were processed, stained with antibodies against CD4, CD3 and TCR Vβ3 and analyzed by flow cytometry.



**Supplemental Figure 4. TCR-ligation-independent Treg suppression is not due to alloreactivity/crossreactivity.** CFSE-labeled OTII.*Rag1*<sup>-/-</sup> Tconv ( $2.5 \times 10^4$ ) were incubated with C57BL/6 DCs ( $6.25 \times 10^3$ ) and varying concentrations of Tregs or control Tconv in the presence of peptide (Ova<sub>326-339</sub>;  $0.3 \mu\text{M}$ ) for 68 h and analyzed by flow cytometry. **A**, CFSE dilution of OTII.*Rag1*<sup>-/-</sup> Tconv incubated with CD25<sup>+</sup>CD45RB<sup>lo</sup> Tregs or AND.*Rag1*<sup>-/-</sup> Tconv (0.5 to 1 Treg:Tconv ratio) is shown in separate histograms with the percentage of Tconv with greater than 1 cell division indicated. **B**, Cells were incubated as in (A) for 68 h, pulsed with [<sup>3</sup>H]thymidine for the last 8 h of culture and Tconv proliferation measured.



**Supplementary Figure 5.** Tregs do not require stimulation through their TCR to suppress Tconv proliferation. *A*, OTII Tconv ( $2.5 \times 10^4$ ) were incubated with irradiated splenocytes (C57BL/6;  $5 \times 10^4$ ) and Tregs ( $1.25 \times 10^4$ ) in the presence of peptide (Ova<sub>326-339</sub>;  $2.0 \mu\text{M}$ ) for 68 h, pulsed with [<sup>3</sup>H]thymidine for the last 8 h of culture and Tconv proliferation measured. *B*, Vβ8<sup>+</sup> Tconv ( $2.5 \times 10^4$ ) were incubated with anti-Vβ8 coated microbeads and Tregs of varying concentrations for 68 h, pulsed with [<sup>3</sup>H]thymidine for the last 8 h of culture and Tconv proliferation measured. Data are representative of 2-3 experiments. \*\*,  $p < 0.005$ , \*,  $p < 0.5$ .